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Key Messages
Treatment
¶ Non-steroidal anti-inflammatory drugs RCTs identified by a systematic
review found that non-steroidal anti-inflammatory drugs reduced sore throat
symptoms both over ≤ 24 hours and at 2–5 days compared with placebo. The
range of benefit was 25–75% over ≤ 24 hours, and 33–93% at 2–5 days.
Non-steroidal anti-inflammatory drugs are associated with gastrointestinal and
renal adverse effects.
¶ Paracetamol Two RCTs identified by a systematic review found that a single
dose of paracetamol reduced acute sore throat pain at 2–3 hours compared
with placebo. Another RCT identified by the review found that paracetamol
three times daily reduced sore throat pain at 2 days compared with placebo.
We found no RCTs of other analgesics in people with sore throat.
¶ Antibiotics One systematic review found that antibiotics reduced the propor-
tion of people with sore throat, fever, and headache at 3 days compared with
placebo. The review found limited evidence from indirect comparisons that the
absolute and relative reduction in sore throat symptoms at 3 days was greater
in people with positive throat swabs for Streptococcus than in people with
negative swabs. It gave no information on adverse effects. We found no RCTs
that assessed the effects of antibiotics in reducing the severity of sore throat
symptoms. Antibiotics may increase the risk of nausea, vomiting, rash, head-
ache, and vaginitis. Widespread antibiotic use may lead to bacterial resistance
to antibiotics.
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¶ Corticosteroids One RCT in children and adolescents with moderate to severe
sore throat infection found that oral dexamethasone reduced throat pain at
24 hours compared with placebo, and reduced the duration of pain. Another
RCT in people with severe sore throat infection identified by a systematic review
found that adding corticosteroids to antibiotics reduced the proportion of
people with sore throat pain at 24 hours compared with adding placebo. It
found more limited evidence that adding corticosteroids to antibiotics also
reduced the duration of pain. The RCTs provided insufficient evidence to assess
adverse effects of corticosteroids in people with sore throat. However, data
from systematic reviews in people with other disorders suggest that corticos-
teroids may be associated with serious adverse effects, although this may be
only after long term use.
¶ Probiotics RCTs suggested that super-colonisation with Streptococcus iso-
lated from healthy individuals apparently resistant to infections from Strepto-
coccus may reduce recurrent sore throat over 2–3 months compared with
placebo. However, at present, super-colonisation with Streptococcus is avail-
able only experimentally. We found no RCTs of other probiotics.
Preventing complications
¶ Antibiotics One systematic review found that antibiotics reduced suppurative
and non-suppurative complications of  haemolytic streptococcal pharyngitis
compared with placebo. However, in industrialised countries, non-suppurative
complications are extremely rare. Widespread antibiotic use may lead to
bacterial resistance to antibiotics.
DEFINITION Sore throat is an acute upper respiratory tract infection that affects
the respiratory mucosa of the throat. Since infections can affect any
part of the mucosa, it is often arbitrary whether an acute upper
respiratory tract infection is called “sore throat” (“pharyngitis” or
“tonsillitis”), “common cold”, “sinusitis”, “otitis media”, or “bron-
chitis” (see figure 1, p 2084). Sometimes, all areas are affected
(simultaneously or at different times) in one illness. In this chapter,
we aim to cover people whose principal presenting symptom is sore
throat. This may be associated with headache, fever, and general
malaise. Suppurative complications include acute otitis media
(most commonly), acute sinusitis, and peritonsillar abscess
(quinsy). Non-suppurative complications include acute rheumatic
fever and acute glomerulonephritis.
INCIDENCE/
PREVALENCE
There is little seasonal fluctuation in sore throat. About 10% of the
Australian population present to primary healthcare services annu-
ally with an upper respiratory tract infection consisting predomi-
nantly of sore throat.1 This reflects about one fifth of the overall
annual incidence.1 However, it is difficult to distinguish between the
different types of upper respiratory tract infection.2
AETIOLOGY/
RISK FACTORS
The causative organisms of sore throat may be bacteria (Strepto-
coccus, most commonly Group A  haemolytic, although some-
times others: Haemophilus influenzae, Moraxella catarrhalis, and
others) or viruses (typically rhinovirus, but also coronavirus, respi-
ratory syncytial virus, metapneumovirus, Ebstein–Barr, and others).
It is difficult to distinguish bacterial from viral infections clinically.
Some features are thought to predict the probability of the infection
being caused by Streptococcus (fever > 38.5 °C; exudate on the
tonsils; anterior neck lymphadenopathy; absence of cough).3 Sore
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throat can be caused by processes other than primary infections,
including gastro-oesophageal reflux, physical or chemical irritation
(from nasogastric tubes or smoke, for example), and occasionally
hay fever. However, we do not consider causes other than primary
infection here.
PROGNOSIS Sore throat infections usually last a few days, with a few symptoms
lasting longer, especially cough.4 The untreated symptoms of sore
throat disappear by 3 days in about 40% of people and untreated
fevers in about 85%. By 1 week, 85% of people are symptom free.
This natural history is similar in Streptococcus positive, negative,
and untested patients.
AIMS OF
INTERVENTION
To relieve symptoms and to prevent suppurative and non-
suppurative complications of sore throat.
OUTCOMES Reduction in severity and duration of symptoms (sore throat pain,
general malaise, headache, fever); reduction in suppurative com-
plications (acute otitis media, acute sinusitis, and quinsy) and
non-suppurative complications (acute rheumatic fever, acute
glomerulonephritis); time off work or school; patient satisfaction;
healthcare utilisation.
METHODS Clinical Evidence search and appraisal May 2004. We excluded
RCTs that only provided data about bacteriological studies of the
throat, because bacteriological cure is not a clinically useful out-
come for spontaneously remitting illness.
QUESTION What are the effects of interventions to reduce
symptoms of acute infective sore throat? New
OPTION ANALGESICS
Two RCTs identified by a systematic review found that a single dose of
paracetamol reduced acute sore throat pain at 2–3 hours compared with
placebo. Another RCT identified by the review found that paracetamol
three times daily reduced sore throat pain at 2 days compared with
placebo. We found no RCTs of other analgesics in people with sore throat.
Benefits: We found one systematic review (search date 1999, 3 RCTs, 312
people with acute sore throat for ≤ 4 days, severity unclear) com-
paring paracetamol (acetaminophen) versus placebo.5 All of the
RCTs found that paracetamol significantly reduced sore throat pain
compared with placebo. Two RCTs (81 adults, 77 children) found
that a single dose of paracetamol significantly reduced sore throat
pain at 2–3 hours compared with placebo (50% greater reduction
than placebo in 1 RCT; P < 0.01; 31% greater reduction than
placebo in the other; P < 0.05). The third RCT (154 children) found
that paracetamol three times daily significantly reduced sore throat
symptoms after 2 days (34% greater reduction than placebo;
P < 0.01). It is unclear how pain was assessed in the RCTs. We
found no RCTs of other analgesics.
Harms: The review gave no information on adverse effects.5
Comment: An update of the review5 is under way.6
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OPTION ANTIBIOTICS
One systematic review found that antibiotics reduced the proportion of
people with sore throat, fever, and headache at 3 days compared with
placebo. The review found limited evidence from indirect comparisons
that the absolute and relative reduction in sore throat symptoms at 3
days was greater in people with positive throat swabs for Streptococcus
than in people with negative swabs. It gave no information on adverse
effects. We found no RCTs that assessed the effects of antibiotics in
reducing the severity of sore throat symptoms. Antibiotics may increase
the risk of nausea, vomiting, rash, headache, and vaginitis. Widespread
antibiotic use may lead to bacterial resistance to antibiotics.
Benefits: We found one systematic review (search date 2003, 26 ran-
domised or quasi-randomised trials, 12 669 people with sore
throat, severity unclear).4 It found that, compared with placebo,
antibiotics slightly but significantly reduced the proportion of people
with symptoms of sore throat at 3 days compared with placebo (14
trials; 930/1966 [47%] with antibiotics v 993/1499 [66%] with
placebo; RR 0.41, 95% CI 0.36 to 0.48; NNT 3, 95% CI 2 to 3).
This represents an average shortening of symptoms by about 1 day.
The reduction in symptoms of sore throat remained significant at
6–8 days (12 trials; 226/1739 [13%] with antibiotics v 199/1079
[18%] with placebo; RR 0.61, 95% CI 0.52 to 0.73; NNT at 7 days
14, 95% CI 6 to 20), an average shortening of 16 hours. The review
also found that antibiotics significantly reduced the proportion of
people with fever at 3 days compared with placebo (7 trials; 87/712
[12%] with antibiotics v 114/622 [23%] with placebo; RR 0.69,
95% CI 0.53 to 0.88; NNT 21, 95% CI 14 to 54) and reduced
headache at 3 days (3 trials; 152/545 [28%] with antibiotics v
117/366 [32%] with placebo; RR 0.79, 95% CI 0.65 to 0.96;
NNT 15, 95% CI 9 to 78). The review found limited evidence from
indirect comparisons that, in people with throat swabs positive for
Streptococcus, the absolute and relative reduction in sore throat
symptoms at 3 days was greater than in people with negative swabs
(positive swabs: 10 trials; 432/1020 [42%] with antibiotics v
516/723 [71%] with placebo; RR 0.56, 95% CI 0.51 to 0.61;
NNT 3, 95% CI 3 to 4; negative swabs: 5 trials; 222/411 [54%] with
antibiotics v 192/265 [73%] with placebo; RR 0.76, 95% CI 0.68 to
0.86; NNT 6, 95% CI 4 to 10). We found no systematic review or
RCTs that assessed severity of sore throat symptoms.
Harms: The systematic review gave no information on adverse effects.
However, data from systematic reviews in people with other disor-
ders suggested that antibiotics were associated with nausea, vom-
iting, headache, skin rash, and vaginitis (see acute bronchitis,
p 2052, and acute otitis media in children, p 324).
Comment: Widespread antibiotic use may lead to bacterial resistance to
antibiotics (see acute bronchitis, p 2052).
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OPTION NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
RCTs identified by a systematic review found that non-steroidal
anti-inflammatory drugs reduced sore throat symptoms both over
≤ 24 hours and at 2–5 days compared with placebo. The range of benefit
was 25–75% over ≤ 24 hours, and 33–93% at 2–5 days. Non-steroidal
anti-inflammatory drugs are associated with gastrointestinal and renal
adverse effects.
Benefits: We found one systematic review (search date 1999, 12 RCTs, 114
people with acute sore throat for ≤ 5 days, severity unclear) com-
paring non-steroidal anti-inflammatory drugs (NSAIDs) versus pla-
cebo.5 The review did not perform a meta-analysis. Seven RCTs
(493 people) identified by the review assessed the effects of
NSAIDs (including 1 RCT of aspirin) over 24 hours or less. All of the
RCTs found that NSAIDs significantly reduced throat pain compared
with placebo. The range of significant improvements in throat pain
compared with placebo ranged from 25–75% (P< 0.05 in all
RCTs). Six RCTs (697 people) identified by the review assessed the
effects of NSAIDs over more than 24 hours. All of the RCTs found
that NSAIDs significantly reduced symptoms (primarily throat pain)
over 2–5 days. The range of significant improvements in symptoms
compared with placebo ranged from 33–93% (P< 0.05 in all
RCTs). It is unclear how pain was assessed in the RCTs.5
Harms: The review gave no information on adverse effects.5 However, data
from systematic reviews in people with other disorders suggested
that NSAIDs were associated with gastrointestinal and renal
adverse effects (see NSAID chapter, p 1700).
Comment: An update of the review5 is under way.6
OPTION CORTICOSTEROIDS
One RCT in children and adolescents with moderate to severe sore throat
infection found that oral dexamethasone reduced throat pain at 24 hours
compared with placebo, and reduced the duration of pain. Another RCT in
people with severe sore throat infection identified by a systematic review
found that adding corticosteroids to antibiotics reduced the proportion of
people with sore throat pain at 24 hours compared with adding placebo. It
found more limited evidence that adding corticosteroids to antibiotics
also reduced the duration of pain. The RCTs provided insufficient
evidence to assess adverse effects of corticosteroids in people with sore
throat. However, data from systematic reviews in people with other
disorders suggest that corticosteroids may be associated with serious
adverse effects, although this may be only after long term use.
Benefits: We found one systematic review (search date 1999, 1 RCT) and
one subsequent RCT.5,7 Versus placebo: The review identified no
RCTs of corticosteroids alone in people with sore throat.5 The
subsequent RCT (98 children and adolescents aged 5–18 years
with moderate to severe sore throat infection defined as the
presence of odynophagia/dysphagia associated with a McGrath
Pain Face Scale of F or higher (happy [A]–sad [I]) compared oral
corticosteroid (dexamethasone 10mg) versus placebo over 24
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hours.7 It was reported only in an abstract. It found that dexam-
ethasone significantly reduced the duration of throat pain com-
pared with placebo (time to being pain free 9.8 hours with dexam-
ethasone v 15.8 with placebo; P < 0.02) and significantly
increased the proportion of people who were completely pain free at
48 hours (proportion with McGrath Pain Face Scale of A or B: 32/40
[80%] with dexamethasone v 27/46 [59%] with placebo;
P = 0.03). Plus antibiotics versus antibiotics alone: The
review5 identified one RCT (51 adults with severe sore throat
infection) comparing adding corticosteroid injection (dexametha-
sone 10mg) to antibiotics versus adding placebo over 24 hours.8 It
found that adding dexamethasone significantly reduced sore throat
pain at 24 hours (mean improvement in pain measured on a visual
analogue scale from 0–30: 1.8 with adding dexamethasone v 1.2
with adding placebo; P < 0.05). It also found limited evidence that
adding dexamethasone significantly reduced the duration of throat
pain compared with placebo (completer analysis in 50% of people
followed up for 7 days; mean time to being pain free reduced from
35 hours to 15 hours; P < 0.02).
Harms: The RCT found no adverse effects associated with oral dexametha-
sone, but may have been too small to detect clinically important
adverse effects. In combination with antibiotics: The review gave
no information on adverse effects.5 However, data from systematic
reviews in people with other disorders suggests that antibiotics may
be associated with serious adverse effects, although this may be
only after long term use. Potential harms of oral corticosteroids are
covered elsewhere in Clinical Evidence (see rheumatoid arthritis,
p 000 and asthma, p 2104).
Comment: More RCTs are needed. An update of the review5 is under way.6
OPTION PROBIOTICS
RCTs suggested that super-colonisation with Streptococcus isolated from
healthy individuals apparently resistant to infections from Streptococcus
may reduce recurrent sore throat over 2–3 months compared with
placebo. However, at present, super-colonisation with Streptococcus is
available only experimentally. We found no RCTs of other probiotics.
Benefits: We found one systematic review5 (search date 1999, 2 RCTs9,10)
and one subsequent RCT11 comparing super-colonisation with
Streptococcus grown from a child resistant to infections from
Streptococcus versus placebo (see comment below). We found no
RCTs of other probiotics. The first RCT (36 people aged 5–40 years
with culture confirmed recurrence of sore throat, all taking antibi-
otics) identified by the review found that super-colonisation with
Streptococcus significantly reduced the proportion of people who
had recurrence of streptococcal sore throat over 3 months com-
pared with placebo (1/17 [6%] with supercolonisation v 11/19
[59%] with placebo; P < 0.001).9 The second RCT (130 people
aged 3–59 years with culture confirmed recurrence of sore throat,
all taking antibiotics) identified by the review found no significant
difference between super-colonisation with Streptococcus and pla-
cebo in the proportion of people who had recurrence of streptococ-
cal sore throat over 8 weeks compared with placebo, although
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fewer people using bacterial spray with Streptococcus had recur-
rence (22% with super-colonisation v 38% with placebo;
P = 0.064).10 The subsequent RCT (342 people, all treated with
antibiotics) found that super-colonisation with Streptococcus sig-
nificantly reduced recurrence over a mean of 3 months compared
with placebo (proportion with recurrent sore throat: 36/189 [19%]
with super-colonisation v 28/93 [30%] with placebo; P = 0.04).11
Harms: Both RCTs found no adverse effects associated with Streptococcus
bacteriological spray.9,11
Comment: Super-colonisation with Streptococcus isolated from healthy indi-
viduals apparently resistant to infections from Streptococcus is
available only experimentally. An update of the review5 is under
way.6
QUESTION What are the effects of interventions to prevent
complications of acute infective sore throat? New
OPTION ANTIBIOTICS
One systematic review found that antibiotics reduced suppurative and
non-suppurative complications of  haemolytic streptococcal pharyngitis
compared with placebo. However, in industrialised countries,
non-suppurative complications are extremely rare. Widespread antibiotic
use may lead to bacterial resistance to antibiotics.
Benefits: We found one systematic review (search date 2003, 26 ran-
domised or quasi-randomised trials, 12 669 people with sore
throat, severity unclear) comparing antibiotics versus placebo to
prevent complications of sore throat infection.4 Acute otitis
media: The review found that antibiotics significantly reduced acute
otitis media at 14 days compared with placebo, although it was a
rare complication in the trials identified (11 trials; 11/2325 [0.5%]
with antibiotics v 28/1435 [2.0%] with placebo; RR 0.26, 95%
CI 0.14 to 0.49; NNT 71, 95% CI 60 to 107).4 Acute rheumatic
fever: It found that antibiotics significantly reduced the proportion
of people who had developed acute rheumatic fever at 2 months
compared with placebo (16 trials; 37/5656 [0.7%] with antibiotics
v 74/4445 [1.8%] with placebo; RR 0.29, 95% CI 0.18 to 0.44;
NNT 77, 95% CI 67 to 98; see comment below).4 The incidence of
acute rheumatic fever has declined with time. The 111 cases of
acute rheumatic fever assessed by the review all occurred in 10
trials undertaken between 1950 and 1961; there were no cases in
the remaining five trials undertaken between 1987 and 2000.
Acute glomerulonephritis: There were too few people who had
acute glomerulonephritis to detect any possible protective effect of
antibiotics in 11 trials (5147 people: 0/2927 [0%] with antibiotics
v 2/2220 [0.1%] with placebo; RR 0.22, 95% CI 0.02 to 2.02; see
comment below). Acute sinusitis: The review found no significant
difference in the proportion of people who had developed acute
sinusitis at 14 days between antibiotics and placebo, but there may
have been too few events to detect a clinically important difference
(8 trials; 4/1545 [0.3%] with antibiotics v 4/842 [0.5%] with
placebo; RR 0.53, 95% CI 0.18 to 1.55). Peritonsillar abscess
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(quinsy): The review found that antibiotics significantly reduced
peritonsillar abscess at 2 months compared with placebo (6 trials;
2/1438 [0.1%] with antibiotics v 23/995 [2.3%] with placebo;
RR 0.14, 95% CI 0.05 to 0.39; NNT 50, 95% CI 46 to 71).
Harms: The systematic review gave no information on adverse effects.
However, data from systematic reviews in people with other disor-
ders suggested that antibiotics were associated with nausea, vom-
iting, headache, skin rash, and vaginitis (see acute bronchitis topic,
p 2052, and acute otitis media in children, p 324).
Comment: Acute rheumatic fever and acute glomerulonephritis associated
with sore throat infection may be related to host antibodies to
Streptococcus cross-reacting with host tissue in the heart and
kidney. See also comment on antibiotics under treatments for sore
throat, p 2079. Widespread antibiotic use may lead to bacterial
resistance to antibiotics (see acute bronchitis, p 2052).
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FIGURE 1 Confusion and overlap in the classification of acute
respiratory infections
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